Recent advances in cancer drug discovery targeting RAS

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Mutated RAS proteins are implicated in 30% of human cancers.
• RAS is a critical oncogene, particularly prevalent in pancreatic, colon, and lung cancers.
• RAS has historically been considered an 'undruggable' target due to difficulties in developing effective therapies.

Purpose of the Study:

• To review recent advances in targeting mutated RAS.
• To highlight novel strategies and their potential for cancer drug development.

Main Methods:

• Analysis of recent scientific literature on RAS-targeted therapies.
• Review of emerging approaches targeting RAS protein structure and binding pockets.
• Examination of specific mutation-targeting strategies, such as KRAS G12C.

Main Results:

• Recent research has identified new binding pockets and structural information for RAS proteins.
• Targeting the KRAS G12C mutation has demonstrated promising preclinical and clinical results.
• Various approaches targeting RAS protein complexes are under investigation.

Conclusions:

• Despite past challenges, novel strategies offer renewed hope for effective RAS-targeted cancer drugs.
• Advances in understanding RAS structure and identifying specific vulnerabilities are driving progress.
• Targeting KRAS G12C and other RAS alterations may lead to new therapeutic options for cancer patients.